Pharmacogenetic predictors associated with reduced risk of secondary to enalapril cough

Currently, the wide prevalence of the development of secondary to ACEIs cough (3.8 to 48 % based on different findings) is one of the core causes of the dramatic impairment of the patients’ quality of life, followed by drug discontinuation. The study had the purpose of revealing the pharmacogenetic predictors associated with the reduced risk of the dry cough AEs secondary to ACEIs, in particular enalapril. The study involved 217 patients with the diagnosis of "essential arterial hypertension", who took enalapril. The patients were assigned to 2 groups: Group 1 (study group): 104 patients without secondary to enalapril adverse drug reactions; and Group 2 (control group): 113 patients with secondary to enalapril cough. All the patients underwent pharmacogenetic testing. The analysis of the distribution of frequencies of the polymorphisms rs4149056 of gene SLCO1B1, rs4459610 of gene ACE, rs1799722 of gene BDKRB2, and rs62151109 of gene CLASP1 has revealed no differences between the group without adverse drug reactions and that with secondary to enalapril dry cough. The study has revealed a statistically significant association between the absence of adverse drug reactions and the presence of the genotype AG of gene SLCO1B1 rs2306283, genotype GG of gene ABO rs8176746 and rs495828.